Focusing on infection prevention to slow antimicrobial resistance rates

Doshi’s article on antimicrobial drug development shows that the Food and Drug Administration is just as vulnerable to a knee jerk reaction as everyone else.1 While sharing Doshi’s concerns, I am struck that the article’s title shows that however many new antimicrobial agents are approved, validl...